

Additional Reading: Bisphosphonates

Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or Diaphyseal Femur. *N Engl J Med*. 2010 Mar 24. [Epub ahead of print] PMID: 20335571 [PubMed - as supplied by publisher]

Borgioli A, Viviani C, Duvina M, et al. Bisphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations. *Therapeutics and Clinical Risk Management* 2009;5:217-227. Publisher and licensee Dove Medical Press Ltd.)

Favia G, Pilolli GP, Maiorano E. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. *J Rheumatol*. 2009 Dec;36(12):2780-7. PMID: 19884275

Lo JC, O’Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. *J Oral Maxillofac Surg*. 2009 Jun 30. PMID: 19772941

Favia G, Pilolli GP, Maiorano E. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. *Bone*. 2009 Sep;45(3):406-13. Epub 2009 May 18. PMID: 19450715

Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: An institutional inquiry. *J Am Dent Assoc*. 2009;140:61-66. PMID: 19119168

Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. *Clin Ther*. 2007 Aug;29(8):1548-58. PMID: 17919538

<http://www.ada.org/prof/resources/topics/osteonecrosis.asp>; Edwards BJ, Hellstein JW, Jacobsen PL, et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. *J Am Dent Assoc*. 2008 Dec;139(12):1674-7. PMID: 19047674

Arrain Y, Masud T. Bisphosphonates and osteonecrosis of the jaw--current thoughts. *Dent Update*. 2009 Sep;36(7):415-9. PMID: 19810397

Estefanía Fresco R, Ponte Fernández R, Aguirre Urizar JM. Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. *Med Oral Patol Oral Cir Bucal*. 2006 Nov 1;11(6):E456-61. PMID: 17072246

Kumar SK, Meru M, Sedghizadeh P. Osteonecrosis of the jaws secondary to bisphosphonate therapy: a case series. *J Contemp Dent Pract*. 2008 Jan 1;9(1):63-9. PMID: 18176650

Sedghizadeh PP, Kumar SK, Gorur A, et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. *J Oral Maxillofac Surg*. 2008 Apr;66(4):767-75. PMID: 18355603

Mak A, Cheung MW, Ho RC, et al. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. *BMC Musculoskelet Disord*. 2009 Sep 21;10:113. PMID: 19772579

Lopes RD, Piccini JP, Hylek EM, et al. Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. *J Thromb Thrombolysis*. 2008 Dec;26(3):167-74. PMID: 18807225

Cummings SR, Schwartz AV, et al. Alendronate and atrial fibrillation. *N Engl J Med*. 2007 May 3;356(18):1895-6. PMID: 17476024

Huang WF, Tsai YW, Wen YW, et al. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. *Menopause*. 2009 Aug 12. [Epub ahead of print] PMID: 19680161

Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. *Arch Intern Med*. 2008 Apr 28;168(8):826-31. PMID: 18443257

Papapetrou PD. Bisphosphonate-associated adverse events. *Hormones (Athens)*. 2009 Apr-Jun;8(2):96-110. PMID: 19570737

Perman MJ, Lucky AW, Heubi JE, et al. Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid. *Arch Dermatol*. 2009 Jan;145(1):95-6. PMID: 19153360

Mishra A. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient. *J Postgrad Med*. 2008 Jul-Sep;54(3):237. PMID: 18626181

Chennuru S, Koduri J, Baumann MA. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. *Intern Med J*. 2008 Aug;38(8):635-7. Epub 2008 Feb 17. PMID: 18284458

Aksoy S, Abali H, Dinçer M, et al. Hypocalcemic effect of zoledronic acid or other bisphosphonates may contribute to their antiangiogenic properties. *Med Hypotheses*. 2004;62(6):942-4. PMID: 15142653

Tanvetyanon T, Choudhury AM. Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa. *Ann Pharmacother*. 2004 Mar;38(3):418-21. PMID: 14970365

Kyrgidis A, Verrou E. Fatigue in bone: A novel phenomenon attributable to bisphosphonate use. *Bone*. 2009 Sep 29. PMID: 19796720

Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. *J Clin Endocrinol Metab.* 2005;90(3):1294-1301. PMID: 15598694

Nevasier AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. *J Orthop Trauma.* 2008;22(5):346-350. PMID: 18448990

Goh Sk, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. *J Bone Joint Surg Br.* 2007;89(3):349-353. PMID: 17356148

Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. *Drug Saf.* 2009;32(9):775-85. PMID: 19670917

Prommer EE. Toxicity of bisphosphonates. *J Palliat Med.* 2009 Nov;12(11):1061-5. PMID: 19922007

Kyrgidis A, Triaridis S, Vahtsevanos K, et al. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. *Expert Rev Anticancer Ther.* 2009 Aug;9(8):1125-34. PMID: 19671032

Gebara SN, Moubayed H. Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. *Am J Health Syst Pharm.* 2009 Sep 1;66(17):1541-7. PMID: 19710437